NetworkNewsBreaks Archive - Page 2240 of 2282

TuesdayJan 24, 2017 9:33 am

NetworkNewsBreaks – Delcath Systems, Inc. (NASDAQ: DCTH) Investigating Novel Therapy for the Treatment of Certain Unresectable Liver Cancers

With an initial potential market opportunity in ocular melanoma liver metastases of between $104 million and $260 million at stake, Delcath Systems (NASDAQ: DCTH) is working with the U.S. FDA toward approval of the company’s Melphalan/Hepatic Delivery System (Melphalan/HDS) chemotherapy system for treatment of certain unresectable liver cancers. The Melphalan/HDS system facilitates the delivery of melphalan directly to the liver and, consequently, allows the administration of higher doses. The blood is then filtered to reduce the level of melphalan and returned to the patient, thereby potentially reducing hematologic side effects. In 2016, Delcath initiated its global FOCUS phase 3 trial in hepatic dominant ocular…

MondayJan 23, 2017 2:04 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 23, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MRNS 31.030% – News: Posts positive preliminary data of CDKL5 candidate for children with severe, rare genetic disorder HMNY 26.88% – News: Names Theodore Fransworth as CEO MDGS 15.15% – News: Receives PO for MUSTE™ system in Italy NQ 13.99% – News: Signs LOI for sale of FL Mobile and Showself, proposed $100M investment BIOL 9.80% – News: Epic Pro laser system receives FDA clearance TERP 9.38% – News: Signs exclusivity agreement with Brookfield…

MondayJan 23, 2017 2:01 pm

NetworkNewsBreaks – U.S. Geothermal, Inc. (NYSE: HTM) Reaffirms 2016 Guidance, Offers Outlook for 2017

U.S. Geothermal (NYSE MKT: HTM) is a renewable energy company on a mission to become the largest pure play independent geothermal power producer, targeting 135 MW by 2021 and a market cap in excess of $1 billion. With the U.S. market demand for electricity rising and creating a growing dependency on non-renewable, non-sustainable resources, U.S. Geothermal plans to accomplish this goal by remaining focused on the development, production and sale of electricity from geothermal energy. The company has confirmed its 2016 guidance for adjusted earnings of $4 million-$8 million on revenues between $29 million-$34 million; for FY17, U.S. Geothermal said…

MondayJan 23, 2017 1:00 pm

NetworkNewsBreaks – AmeriCann, Inc. (ACAN) Building One of the Nation’s Largest MMJ Facilities

AmeriCann (OTCQX: ACAN), a medical marijuana facility developer based in Denver, Colorado, recently launched the first phase of its planned MMJ facility in Massachusetts, and retained highly-experienced Campanelli Construction as general contractor. In the first quarter of 2017, AmeriCann plans to break ground on the Massachusetts Medical Cannabis Center – which is approved for 1 million square feet – and expects to have its preferred partners start cannabis production on the property by fall. When complete, the facility will be one of the largest and most technologically-advanced medical marijuana centers in the United States. The first phase of the project…

MondayJan 23, 2017 12:57 pm

NetworkNewsBreaks – RMG Networks Holding Corp. (NASDAQ: RMGN) Innovations Meet Demand for Digital Signage Messaging

For over 35 years, RMG Networks Holding (NASDAQ: RMGN) has been going beyond traditional communications to help businesses increase productivity, efficiency and engagement through digital signage messaging. Today, many companies are turning toward digital signage solutions to easily display their visual data on multiple devices for a variety of initiatives. When it comes to corporate communications, for example, RMG delivers real-time internal communications directly to employee desktops and mobile devices, enabling 100% reach, optimal impact, and a unique way to boost employee engagement and productivity. With a strong portfolio of hardware and software design, RMG in less than three years…

MondayJan 23, 2017 12:52 pm

NetworkNewsBreaks – Resonant, Inc. (NASDAQ: RESN) Aims to Change Mobile Industry with Proprietary RF Filter Design

The mobile industry is still using radio frequency filters designed based on technology that has hardly changed over the past century and therefore is not able to fully meet the industry’s new challenges and requirements. Resonant, Inc. (NASDAQ: RESN), a developer of software tools and designs for radio frequency front-ends (RFFE) filters, is looking to change that via its proprietary Infinite Synthesized Networks™ technology. ISN™ has the potential of answering one of the industry’s biggest challenges: being able to tune or reconfigure RF filters to work across several bands simultaneously. Resonant is working on developing innovative single-band and tunable designs…

MondayJan 23, 2017 12:49 pm

NetworkNewsBreaks – Digital Ally, Inc. (NASDAQ: DGLY) Capitalizing on the Increased Use of Mobile Devices

With the rampant application and use of mobile technologies, Digital Ally, Inc. (NASDAQ: DGLY) has designed a complete evidence management solution for law enforcement and security agencies, accessible through a mobile application called VuVault Go™. The app gives law enforcement officers full control of evidence, as well as the ability to take notes and playback videos. As a result, agencies have control over digital evidence while on the job. CJIS-compliant, VuVault Go™ offers secure access to recordings on both Android and iOS devices. The mobile application is part of the company’s VuVault® platform, which also includes VuVault.Com™, a secure Internet-based…

FridayJan 20, 2017 1:26 pm

NetworkNewsBreaks – Concert Pharmaceuticals’ (NASDAQ: CNCE) CTP-656 Obtains Orphan Drug Designation from FDA

Concert Pharmaceuticals (NASDAQ: CNCE) this morning reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for CTP-656, a next generation CFTR potentiator for the treatment of cystic fibrosis. The designation provides incentives such as tax credits related to clinical trial expenses, an exemption from the FDA user fee, FDA assistance in clinical trial design, and potential market exclusivity for seven years following approval. In December 2016, Concert initiated a phase 2 trial in the U.S. evaluating CTP-656 in cystic fibrosis patients with gating mutations. Topline data from the ongoing phase 2 trial is expected by…

FridayJan 20, 2017 12:36 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 20, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MTP 11.60% – News: Provides trading update GRWG 8.84% – News: Las Vegas store officially opens MTNB 5.00% – News: Raises $13.5M from exercise of warrants BSGM 3.77% – News: Issues shareholder letter CRTN 3.64% – News: Reports persistent growth in network transformation FH 3.37% – News: To ring the Nasdaq opening bell January 23 to celebrate closing of XpresSpa acquisition FNMA 2.38% – News: Chief economist comments on 2017 outlook BLDP 2.25% –…

FridayJan 20, 2017 12:34 pm

NetworkNewsBreaks – Second Sight Medical Products, Inc. (NASDAQ: EYES) Sees Mounting Potential for Argus® II “Bionic Eye” Implants

Second Sight Medical Products (NASDAQ: EYES) develops, manufactures and markets implantable prosthetic devices to restore functional vision to blind patients. The company’s Argus II System is an implantable neurostimulation device that uses electrical stimulation of the retina to replace the function of the defunct photo-receptors in retinitis pigmentosa patients. Second Sight wrapped up 2016 with an announcement that for the first time in the UK, the publicly-funded NHS system would fund blind patients with retinitis pigmentosa (RP) to receive treatment with Second Sight’s innovative Argus® II Retinal Prosthesis System (Argus II) “bionic eye.” The company most recently announced a rights…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks